Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice

Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol 2020; 83: 709–717. DOI: https://doi.org/10.1016/j.jaad.2020.03.126

Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 2022; 87: 373–374.e5. DOI: https://doi.org/10.1016/j.jaad.2022.04.013

Gilaberte Y, Fernández-Figueras MT. Tirbanibulina: revisión de su mecanismo de acción novedoso y de cómo encaja en el tratamiento de la queratosis actínica. Actas Dermo-Sifiliográficas 2021; 113: 58–66. DOI: https://doi.org/10.1016/j.ad.2021.07.006

Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 Trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 2021; 384: 512–520. DOI: https://doi.org/10.1056/NEJMoa2024040

Heppt MV, Dykukha I, Graziadio S, Salido-Vallejo R, Chapman-Rounds M, Edwards M. Comparative efficacy and safety of tirbanibulin for actinic keratosis of the face and scalp in Europe: a systematic review and network meta-analysis of randomized controlled trials. J Clin Med 2022; 11: 1654. DOI: https://doi.org/10.3390/jcm11061654

Li Pomi F, Vaccaro M, Pallio G, Rottura M, Irrera N, Borgia F. Tirbanibulin 1% ointment for actinic keratosis: results from a real-life study. Med Kaunas Lith 2024; 60: 225. DOI: https://doi.org/10.3390/medicina60020225

Campione E, Rivieccio A, Gaeta Shumak R, Costanza G, Cosio T, Lambiase S, et al. Preliminary evidence of efficacy, safety, and treatment satisfaction with tirbanibulin 1% ointment: a clinical perspective on actinic keratoses. Pharm Basel Switz 2023; 16: 1686. DOI: https://doi.org/10.3390/ph16121686

Kirchberger MC, Gfesser M, Erdmann M, Schliep S, Berking C, Heppt MV. Tirbanibulin 1% ointment significantly reduces the actinic keratosis area and severity index in patients with actinic keratosis: results from a real-world study. J Clin Med 2023; 12: 4837. DOI: https://doi.org/10.3390/jcm12144837

Mansilla-Polo M, Abril-Pérez C, Martín-Torregrosa D, López-Davia J, de Unamuno-Bustos B, Torres-Navarro I, et al. Effectiveness, safety and satisfaction of 1% tirbanibulin ointment in the treatment of actinic keratoses: a prospective study in real clinical practice. Australas J Dermatol 2023; 64: 560–564. DOI: https://doi.org/10.1111/ajd.14151

Pellacani G, Schlesinger T, Bhatia N, Berman B, Lebwohl M, Cohen JL, et al. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. J Eur Acad Dermatol Venereol 2024; 38: 3–15. DOI: https://doi.org/10.1111/jdv.19636

Bhatia N, Lain E, Jarell A, DuBois J, Tamarit ML, Falques M, et al. Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: a phase 3 study. JAAD Int 2024; 17: 6–14. DOI: https://doi.org/10.1016/j.jdin.2024.07.001

Iglesias-Puzas Á, Conde-Taboada A, Campos-Muñoz L, Sirgado-Martínez A, López-Bran E. 1% tirbanibulin ointment for actinic keratoses on upper extremities: a retrospective case review study. Acta Derm Venereol 2023; 103: adv15296. DOI: https://doi.org/10.2340/actadv.v103.15296